LY305 explained

Legal Status:	Investigational
Cas Number:	1430230-83-3
Pubchem:	71543393
Chemspiderid:	58921204
Chembl:	3764185
Stdinchi:	1S/C14H17ClN2O/c1-9-11(6-5-10(8-16)13(9)15)17-12-4-3-7-14(12,2)18/h5-6,12,17-18H,3-4,7H2,1-2H3/t12-,14-/m1/s1
Stdinchikey:	CXFSVKGROITHRY-TZMCWYRMSA-N
Smiles:	CC1=C(C=CC(=C1Cl)C#N)N[C@@H]2CCC[C@@]2(C)O
Iupac Name:	2-Chloro-4-(1R,2R)-2-hydroxy-2-methylcyclopentylamino]-3-methylbenzonitrile
C:	14
H:	17
Cl:	1
N:	2
O:	2

LY305 is a transdermally bioavailable selective androgen receptor modulator (SARM) developed by Eli Lilly for the treatment of osteoporosis in men. Its chemical structure includes N-arylhydroxyalkyl. A phase one trial found promising results.^{[1] [2] [3]}

Notes and References

1. Krishnan . V. . Patel . N. J. . Mackrell . J. G. . Sweetana . S. A. . Bullock . H. . Ma . Y. L. . Waterhouse . T. H. . Yaden . B. C. . Henck . J. . Zeng . Q. Q. . Gavardinas . K. . Jadhav . P. . Saeed . A. . Garcia-Losada . P. . Robins . D. A. . Benson . C. T. . Development of a selective androgen receptor modulator for transdermal use in hypogonadal patients . Andrology . 2018 . 6 . 3 . 455–464 . 10.1111/andr.12479. free .
2. Christiansen . Andrew R. . Lipshultz . Larry I. . Hotaling . James M. . Pastuszak . Alexander W. . Selective androgen receptor modulators: the future of androgen therapy? . Translational Andrology and Urology . March 2020 . 9 . Suppl 2 . S135–S148 . 10.21037/tau.2019.11.02 . 32257854 . 7108998 . 2223-4683 . free .
3. Mohler ML, Sikdar A, Ponnusamy S, Hwang DJ, He Y, Miller DD, Narayanan R. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer. Int J Mol Sci. 2021 Feb 20;22(4):2124.